Gene-Modified Cell Therapy to Target CD7 for Oncology is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase I drugs for Peripheral T-Cell Lymphomas (PTCL) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene-Modified Cell Therapy to Target CD7 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene-Modified Cell Therapy to Target CD7 for Oncology overview

Gene-modified cell therapy is under development for the treatment of refractory or relapsed T-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic lymphoma, T-cell non-Hodgkin lymphoma, extranodal NK/ T-cell lymphoma nasal, peripheral T-cell lymphoma, enteropathy associated T-cell lymphoma and anaplastic T-cell lymphoma. The therapeutic candidate comprises allogenic T cells, genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing CD7.

For a complete picture of Gene-Modified Cell Therapy to Target CD7 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.